A recent review found that the incidence of VAP was higher among patients with COVID-19 than among patients with other causes of ARDS. Researchers also determined that VAP in patients with COVID-19 was frequently associated with treatment failure and recurrences, as well as abscess and empyema.
Researchers found that the combined effects of the extensive use of immunosuppressive agents plus COVID-19–associated immune alteration and pulmonary infarction explained high VAP incidence. They further highlighted the increasing use of multiplex polymerase chain reaction during the COVID-19 pandemic, which shortened the delay of bacterial identification and had an uncertain impact on appropriateness of antibacterial therapy and prognosis.
Learn more about VAP.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Rapid Review Quiz: Hospital-Acquired Pneumonia - Medscape - Sep 15, 2022.